AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00734682
Drug: Nanoliposomal CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
Trial: NCT02833948
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)
Trial: NCT02661958
Drug: S6G5T-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day topical cream
Trial: NCT02661958
Drug: S6G5T-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day topical cream
Trial: NCT02661958
Drug: S6G5T-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day topical cream
Trial: NCT04044222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02661958
Drug: S6G5T-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day topical cream
Trial: NCT00970632
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet po QD for 12 weeks
Trial: NCT00970632
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule po QD for 12 weeks
Trial: NCT01930188
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
Trial: NCT01930188
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Trial: NCT04685395
Drug: Ribamipide gargle \benzdymine HCL gargel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ribamipide gargle 6 time daily 5ml dosage
Trial: NCT01327014
Drug: XueZhiKang (XZK), a botanic product with multiple components
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of study drug twice a day for 12 weeks.
Trial: NCT01327014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules twice a day for 12 weeks.
Trial: NCT03780465
Drug: NOX66 (A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idronoxil formulated in suppository base A
Trial: NCT03780465
Drug: NOX66 (B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idronoxil formulated in suppository base B
Trial: NCT01624857
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
Trial: NCT01624857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
Trial: NCT02027662
Drug: Osvaren Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02027662
Drug: Osvaren film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02588716
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
Trial: NCT02848482
Drug: Irrigation
RxNorm normalized name: Eye Irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
Trial: NCT00736489
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, single dose
Trial: NCT00736489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, single dose
Trial: NCT02450084
Drug: IV-PCA containing Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
Trial: NCT01921192
Drug: Folic Acid, vit B6 and B12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00482911
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25-50 mg by mouth once daily on days 1-28.
Trial: NCT00257894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules containing inert filler taken orally for a total of 12 days
Trial: NCT01921192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01898221
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
Trial: NCT04182854
Drug: Furosemid hydrochlorothiazide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
Trial: NCT00855010
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one daily
Trial: NCT01435096
Drug: BN80927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
Trial: NCT00921102
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine
Trial: NCT03024684
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet daily
Trial: NCT03142542
Drug: ZYDENA TAB.75mg(Udenafil 75mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
Trial: NCT03142542
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
Trial: NCT03605862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for five days
Trial: NCT04403503
Drug: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
RxNorm normalized name: Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
Trial: NCT04403503
Drug: Cyanoacrylate, Isobutyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
Trial: NCT02630095
Drug: Nadroparin Calcium and Warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
Trial: NCT03205488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules taken once daily
Trial: NCT00681915
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00177307
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
Trial: NCT01370681
Drug: Period I : HKB0701 and SLM0807, Period II : CJ30001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01370681
Drug: Period I : CJ30001, Period II : HKB0701 and SLM0807
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00921063
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg capsule, BID for 4 weeks
Trial: NCT03737708
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01460654
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Gel (Fortesta) 40mg daily.
Trial: NCT00027014
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00258115
Drug: salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02541669
Drug: TAK-491 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-491 placebo-matching tablets
Trial: NCT01747590
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01191775
Drug: PNT2258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
Trial: NCT01655849
Drug: z160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01655849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03028857
Drug: Choline
RxNorm normalized name: Choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Trial: NCT03028857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
Trial: NCT02342652
Drug: ASLAN003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Trial: NCT02342652
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
Trial: NCT02947880
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
Trial: NCT02947880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
Trial: NCT02151994
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02151994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01964547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
Trial: NCT02394613
Drug: ANX776
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection
Trial: NCT03991013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Trial: NCT00686140
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg/day, twice a day, 12 weeks
Trial: NCT00686140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day, 12 weeks
Trial: NCT00343785
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00343785
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03905512
Drug: KRYSTEXXA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT03747068
Drug: Anti-TNF Drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02509858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with 50μg of placebo, once daily, for two months.
Trial: NCT02281266
Drug: nucleoside analog (suggest to use entecavir)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03507998
Drug: CGX1321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGX1321 capsules for oral administration
Trial: NCT01729338
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
Trial: NCT04425902
Drug: GSK3640254 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
Trial: NCT04425902
Drug: Caffeine 200 mg
RxNorm normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine will be available as oral tablets at unit dose strength of 200 mg.
Trial: NCT04425902
Drug: Flurbiprofen 100 mg
RxNorm normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
Trial: NCT03234517
Drug: Vaginal Probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Probiotic
Trial: NCT04425902
Drug: Pravastatin 40 mg
RxNorm normalized name: pravastatin 40 mg oral tablet
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
Trial: NCT01453478
Drug: GSK1325756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCR2 antagonist
Trial: NCT04065451
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine in the submucosal injection fluid
Trial: NCT00624195
Drug: FDA Approved Antiretroviral Therapy (see list below)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
Trial: NCT00602498
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04535531
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically once daily
Trial: NCT02233920
Drug: Ventilat® - metered dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00161642
Drug: CMD-193
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01662921
Drug: NPH
RxNorm normalized name: ZENPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
Trial: NCT03492398
Drug: HY209
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Trial: NCT03547206
Drug: RPh201 Cohort A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Trial: NCT03547206
Drug: RPh201 Cohort B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
Trial: NCT02659787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02405260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02196259
Drug: Anesthetics, Dissociative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
Trial: NCT00329914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pessaries containing peanut oil
Trial: NCT03654781
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
Trial: NCT00837044
Drug: Migraine rescue medication of choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine rescue medication of choice
Trial: NCT03378297
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid tablets 160 mg x1 orally
Trial: NCT02430259
Drug: Weekly INH / RRT given by DOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
Trial: NCT02038049
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of VAY736 (10 mg/kg)
Trial: NCT02038049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to VAY736
Trial: NCT00413283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection.
Trial: NCT01681563
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01495884
Drug: non-pegylated liposomal doxorubicon (Myocet™)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00058422
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00058422
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01450748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks